Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Novartis says biosimilar rituximab accepted for review by FDA

Written by: | no-reply@reuters.com | Dated: Tuesday, September 12th, 2017

 

ZURICH (Reuters) – Novartis AG said on Tuesday its biosimilar rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis was accepted for review by the U.S. Food and Drug Administration (FDA).

Rituximab, made by Novartis’ unit Sandoz, has been proposed as a biosimilar to Roche’s reference medicine Rituxan, Novartis said in a statement.

Rituximab was approved in Europe in June, Novartis said.

 

Reporting by Silke Koltrowitz

 

Reuters source:

http://www.reuters.com/article/us-novartis-rituximab/novartis-says-biosimilar-rituximab-accepted-for-review-by-fda-idUSKCN1BN0HG

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2017 Focus: Pharma Innovators, Top 200 Meds, Lions Health and more!

Subscribe

Ad Right Bottom

Main Navigation